(Sharecast News) - Hutchmed said on Wednesday that it has initiated a global phase one clinical development programme for HMPL-A251, marking the first clinical-stage candidate from its next-generation Antibody-Targeted Therapy Conjugate platform.
The AIM-traded firm said the first-in-human phase one/2a, open-label, multicentre study was evaluating HMPL-A251 as a monotherapy in adult...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE